Biohaven Ltd. Files 8-K with Corporate Updates

TL;DR

Biohaven Ltd. filed an 8-K on 5/17/24 with corporate info and past name change details.

AI Summary

Biohaven Ltd. filed an 8-K on May 17, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at 215 Church Street, New Haven, Connecticut, and its telephone number. It also notes a former company name, Biohaven Research Ltd., with a name change date of June 29, 2022.

Why It Matters

This filing provides essential corporate information and updates for Biohaven Ltd., which is important for investors and stakeholders to track the company's official details and history.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational risks.

Key Players & Entities

• Biohaven Ltd. (company) — Registrant
• May 17, 2024 (date) — Date of earliest event reported
• 215 Church Street, New Haven, Connecticut (location) — Principal executive offices
• Biohaven Research Ltd. (company) — Former company name
• June 29, 2022 (date) — Date of name change

FAQ

Filing Documents

• bhvn-20240517.htm (8-K) — 23KB
• exhibit51maplesopinionandc.htm (EX-5.1) — 33KB
• image_0a.jpg (GRAPHIC) — 82KB
• 0001935979-24-000053.txt ( ) — 279KB
• bhvn-20240517.xsd (EX-101.SCH) — 2KB
• bhvn-20240517_lab.xml (EX-101.LAB) — 21KB
• bhvn-20240517_pre.xml (EX-101.PRE) — 12KB
• bhvn-20240517_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On May 17, 2024, Biohaven Ltd. (the "Company") filed a prospectus supplement to its Registration Statement on Form S-3 (No. 333-274822) (the "Registration Statement") filed with the U.S. Securities and Exchange Commission (the "Commission"), under the Securities Act of 1933, as amended, with respect to the resale by the selling shareholders named therein of 211,418 common shares, no par value, of the Company that were issued by the Company to such selling shareholders as share consideration in connection with the transactions and business arrangements described therein. In connection with the filing of the prospectus supplement, the Company is filing a legal opinion as Exhibit No. 5.1 to this Current Report on Form 8-K, which is incorporated by reference into the Registration Statement.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 5.1 Opinion of Maples & Calder. 23.1 Consent of Maples & Calder (included in Exhibit 5.1). 104 The cover page of this Current Report on Form 8-K formatted as Inline XBRL. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 17, 2024 Biohaven Ltd. By: /s/ Matthew Buten Matthew Buten Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR